Last reviewed · How we verify
ACP-204
ACP-204 is a muscarinic M1 receptor agonist that enhances cholinergic neurotransmission to improve cognitive and psychiatric symptoms.
ACP-204 is a muscarinic M1 receptor agonist that enhances cholinergic neurotransmission to improve cognitive and psychiatric symptoms. Used for Cognitive impairment associated with schizophrenia, Negative symptoms of schizophrenia, Psychosis in Alzheimer's disease.
At a glance
| Generic name | ACP-204 |
|---|---|
| Also known as | ACP-204 Tartrate |
| Sponsor | ACADIA Pharmaceuticals Inc. |
| Drug class | Muscarinic M1 receptor agonist |
| Target | M1 muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | Phase 3 |
Mechanism of action
ACP-204 selectively activates M1 muscarinic acetylcholine receptors in the brain, which are involved in cognition, attention, and mood regulation. By increasing M1 receptor signaling, the drug aims to enhance acetylcholine-mediated neurotransmission, potentially improving cognitive deficits and negative symptoms in neuropsychiatric disorders. This mechanism is distinct from typical antipsychotics and may offer cognitive benefits in conditions like schizophrenia and Alzheimer's disease psychosis.
Approved indications
- Cognitive impairment associated with schizophrenia
- Negative symptoms of schizophrenia
- Psychosis in Alzheimer's disease
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
Key clinical trials
- Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis (PHASE3)
- Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis (PHASE2)
- ACP-204 in Adults With Alzheimer's Disease Psychosis (PHASE2, PHASE3)
- ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACP-204 CI brief — competitive landscape report
- ACP-204 updates RSS · CI watch RSS
- ACADIA Pharmaceuticals Inc. portfolio CI